Please select the option that best describes you:
How will you use REGEN-COV (casirivimab/imdevimab-monoclonal antibody treatment recently approved under EUA as post-exposure prophylaxis for Covid) in rheumatic patients on immunosuppressive therapy?
Would you consider this for patients on B-cell depleting therapies or more broadly for other immunosuppressive agents?
Answer from: at Academic Institution
Like most other treatments, I've tried to triage use of REGEN-COV post-exposure prophylaxis (PEP) based on the other risk factors that a patient has:The NEJM study published by O'Brien et al. PMID 34347950 did show marked benefit in REGEN-COV post-exposure prophylaxis vs. placebo in the (a) decreasi...
Sign in or Register to read more
Answer from: at Community Practice
I have a rheumatoid arthritis patient with ILD whose husband had COVID. She could not get post-exposure prophylaxis in Texas without a positive test. I appealed to several centers. We did get her husband treated with monoclonal antibodies to decrease the viral load. She self-tested daily at home for...